CVA Family Office LLC Increases Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

CVA Family Office LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.8% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 1,530 shares of the medical research company’s stock after buying an additional 84 shares during the period. CVA Family Office LLC’s holdings in Thermo Fisher Scientific were worth $761,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of TMO. Norges Bank bought a new stake in Thermo Fisher Scientific during the fourth quarter worth about $3,149,754,000. GAMMA Investing LLC lifted its stake in shares of Thermo Fisher Scientific by 60,610.9% in the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company’s stock worth $1,203,859,000 after buying an additional 2,415,346 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 86.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company’s stock worth $1,604,338,000 after buying an additional 1,433,444 shares in the last quarter. Kovitz Investment Group Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 1,905.4% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company’s stock worth $469,889,000 after buying an additional 858,193 shares in the last quarter. Finally, Proficio Capital Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 68,617.0% in the fourth quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company’s stock worth $396,810,000 after buying an additional 761,649 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 3.2%

Shares of NYSE TMO opened at $402.12 on Friday. The firm’s 50-day moving average price is $416.80 and its 200-day moving average price is $492.39. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $151.80 billion, a price-to-earnings ratio of 24.33, a P/E/G ratio of 2.99 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 12-month low of $390.50 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm’s revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.11 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.43%. Thermo Fisher Scientific’s payout ratio is 10.09%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.33% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on TMO shares. Scotiabank dropped their target price on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating on the stock in a research note on Friday, April 25th. UBS Group lowered their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Wednesday, April 23rd. Barclays lowered their price objective on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. Finally, Citigroup decreased their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $605.30.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.